Related Experiment Videos
Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA - walshc@cshs.org.
Introduction:
Poly(ADP-ribose) polymerase (PARP) inhibitors are a targeted therapy option for ovarian cancer. The goal of this review was to organize and summarize the clinical trials evaluating PARP inhibitor therapy in ovarian cancer as monotherapy, maintenance therapy after partial or complete remission to therapy or as a part of a combination regimen.
Evidence Acquisition:
PubMed, ClinicalTrials.gov, data from the United States Food and Drug Administration (US FDA) and proceedings from scientific conferences were searched for published and unpublished data pertaining to clinical trials and approvals of PARP inhibitor use in ovarian cancer.
Evidence Synthesis:
There have been 36 published phase 1, 2 and 3 studies evaluating the use of olaparib, niraparib, veliparib and rucaparib in ovarian cancer. Olaparib and rucaparib have been approved by the US FDA as monotherapy for advanced recurrent ovarian cancer. Niraparib and olaparib have been approved by the US FDA for maintenance therapy after partial or complete remission in recurrent ovarian cancer. There are currently ten phase 3 trials evaluating PARP inhibitors at various timepoints in ovarian cancer therapy including at the time of primary adjuvant therapy, as maintenance therapy after primary chemotherapy, as monotherapy for recurrent cancer and as maintenance therapy after chemotherapy for recurrence.
Conclusions:
The landscape of PARP inhibitor use for ovarian cancer is rapidly evolving and PARP inhibitors have become more available as a targeted therapy option for ovarian cancer treatment.
Insights
Poly(ADP-ribose) polymerase (PARP) inhibitors are increasingly used for ovarian cancer. This review summarizes clinical trials of PARP inhibitors as monotherapy, maintenance, or combination treatments, showing their growing role in treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Poly(ADP-ribose) polymerase (PARP) inhibitors represent a targeted therapy for ovarian cancer.
- Their use spans monotherapy, maintenance, and combination regimens.
Purpose of the Study:
- To organize and summarize clinical trials of PARP inhibitors in ovarian cancer.
- To review their efficacy in various treatment settings.
Main Methods:
- Searched PubMed, ClinicalTrials.gov, US FDA data, and conference proceedings.
- Included published and unpublished data on PARP inhibitor clinical trials and approvals.
Main Results:
- 36 phase 1-3 studies evaluated olaparib, niraparib, veliparib, and rucaparib in ovarian cancer.
- Olaparib and rucaparib are FDA-approved for advanced recurrent ovarian cancer monotherapy.
- Niraparib and olaparib are FDA-approved for maintenance therapy in recurrent ovarian cancer.
Conclusions:
- PARP inhibitors are a rapidly evolving and increasingly available targeted therapy for ovarian cancer.
- Their application in ovarian cancer treatment is expanding across different stages and settings.